| Main Title |
Kinesins and Cancer [electronic resource] / |
| Type |
EBOOK |
| Other Authors |
|
| Publisher |
Springer Netherlands : Imprint: Springer, |
| Year Published |
2015 |
| Call Number |
RC261-271 |
| ISBN |
9789401797320 |
| Subjects |
Medicine ;
Oncology ;
Biochemistry ;
RNA-ligand interactions ;
Cytology
|
| Internet Access |
|
| Collation |
X, 271 p. 50 illus., 32 illus. in color. online resource. |
| Notes |
Due to license restrictions, this resource is available to EPA employees and authorized contractors only |
| Contents Notes |
Preface -- The kinesin superfamily -- The discovery and development of Eg5 inhibitors for the clinic -- Mechanism of action of Eg5 inhibitors -- Clinical trials of mitotic kinesin inhibitors -- Kif15; a useful target for anti-cancer therapy?.- Down-regulating CENP-E activity: for better or for worse -- The human kinesin-14 motor KifC1/HSET is an attractive anti-cancer drug target.-Kinesin-13 Microtubule Depolymerizing Proteins as targets for cancer therapy -- Chromokinesins in genome maintenance and cancer -- Kif14: a clinically relevant kinesin and potential target for cancer therapy -- Kinesin-8 members and their potential as biomarker or therapeutic target -- The kinesin-6 members MKLP1, MKLP2 and MPP -- Non-motor spindle proteins as cancer chemotherapy targets -- Inhibitors of mitotic kinesins for cancer treatment: consequences for neurons -- Index. This interdisciplinary volume collates research work on kinesins and cancer. Authors attempt to validate members of the kinesin superfamily as potential targets for drug development in cancer chemotherapy. The work begins by highlighting the importance of kinesins, summarising current knowledge and how they are shown to be crucial for mitosis. Chapters go on to explore how this family of proteins are emerging as a novel target for chemotherapeutic intervention and drug development. Readers will learn how kinesins travel along microtubules to fulfill their many roles in intracellular transport or cell division. Several compounds that inhibit two mitotic kinesins (called Eg5 and CENP-E) have entered Phase I and II clinical trials and are explored in these chapters. Additional mitotic kinesins are currently being validated as drug targets, raising the possibility that the repertoire of kinesin-based drug targets may expand in the future. The book is suitable as a reference standard for the field of kinesins and cancer. It will interest those in academia and pharmaceutical companies, and anyone with an interest in the medical relevance of these proteins, which cutting edge methodologies are now enabling us to understand in astonishing detail. |
| Place Published |
Dordrecht |
| Corporate Au Added Ent |
SpringerLink (Online service) |
| Host Item Entry |
Springer eBooks |
| PUB Date Free Form |
2015 |
| BIB Level |
m |
| Medium |
computer |
| Content |
text |
| Carrier |
online resource |
| Cataloging Source |
OCLC/T |
| OCLC Time Stamp |
20150519175234 |
| Language |
eng |
| Origin |
SPRINGER |
| Type |
EBOOK |
| OCLC Rec Leader |
03638nam a22004815i 45 |
